Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
- Pierre-Yves CremieuxAffiliated withAnalysis Group/EconomicsDepartment of Economics, University of Quebec Email author
- , Stan N. FinkelsteinAffiliated withSloan School of Management, Massachusetts Institute of Technology
- , Ernst R. BerndtAffiliated withSloan School of Management, Massachusetts Institute of Technology
- , Jeffrey CrawfordAffiliated withDuke University Medical Center
- , Mitchell B. SlavinAffiliated withClinical Affairs, Ortho Biotech Inc.
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted life-years (QALYs) can provide the basis for an appropriate measure of the value of supportive care interventions.
Design: A modelling study drawing cost and effectiveness assumptions from a literature review and from 3 US clinical trials involving more than 4500 patients with cancerwhowere treatedwith chemotherapy, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer.
Main outcome measures and results: When compared with transfusions, epoetin is cost effective under varying assumptions, whether effectiveness is measured by haemoglobin level or quality of life. Specifically, under a base-case scenario, the effectiveness resulting from $US1 spent on standard care can be achieved with only $US0.81 of epoetin care. Due in part to the health-state dependence of the significance patients attach to incremental changes in their responses on the linear analogue scale, cost per QALY results are ambiguous in this supportive care context.
Conclusions: Under a broad range of plausible assumptions, epoetin can be used cost effectively in the treatment of anaemic patients with cancer. Further, QALYs have limited applicability here because, as a short term supportive treatment, epoetin enhances the quality but not the length of life. Future research would benefit from the establishment of consistent values for quality-of-life changes across patients and health status, and the extension of the QALY framework to supportive care.
- Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
Volume 16, Issue 5 , pp 459-472
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Analysis Group/Economics, One Brattle Square, Cambridge, Massachusetts, 02138, USA
- 2. Department of Economics, University of Quebec, Montreal, Quebec, Canada
- 3. Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
- 4. Duke University Medical Center, Durham, North Carolina, USA
- 5. Clinical Affairs, Ortho Biotech Inc., Raritan, New Jersey, USA